Table 2.
Multivariable Cox regression analyses for the composite endpoint of all-cause mortality and readmission due to heart failure
| HR (95% CI) | p value | |
|---|---|---|
| Composite endpoint | ||
| Stanniocalcin-2a | 2.06 (1.13–3.75) | 0.018 |
| IGFBP-4a | 1.73 (1.14–2.64) | 0.010 |
| Killip–Kimball class III–IV | 1.40 (1.13–1.74) | 0.002 |
| NT-ProBNPa | 1.21 (1.07–1.37) | 0.002 |
| Age | 1.06 (1.04–1.08) | < 0.001 |
| LVEF | 0.97 (0.95–0.98) | < 0.001 |
| All-cause mortality | ||
| Stanniocalcin-2a | 2.23 (1.16–4.29) | 0.017 |
| Killip–Kimball class II–IV | 1.64 (1.30–2.08) | < 0.001 |
| NT-ProBNPa | 1.18 (1.02–1.36) | 0.028 |
| Age | 1.07 (1.05–1.10) | < 0.001 |
| LVEF | 0.97 (0.95–0.99) | 0.002 |
| Readmission due to heart failure | ||
| Stanniocalcin-2a | 3.42 (1.22–9.60) | 0.020 |
| Prior myocardial infarction | 2.85 (1.32–6.16) | 0.008 |
| Diabetes mellitus | 2.36 (1.22–4.58) | 0.011 |
| Female sex | 2.21 (1.15–4.28) | 0.018 |
| Age | 1.04 (1.01–1.07) | 0.005 |
| LVEF | 0.94 (0.92–0.97) | < 0.001 |
IGFBP-4 insulin-like growth factor binding protein-4, LVEF left ventricular ejection fraction
aHRs (95% CIs) are reported per 1-SD increment of natural log-transformed plasma levels